Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis.

Marcy O, Borand L, Ung V, Msellati P, Tejiokem M, Huu KT, Do Chau V, Ngoc Tran D, Ateba-Ndongo F, Tetang-Ndiang S, Nacro B, Sanogo B, Neou L, Goyet S, Dim B, Pean P, Quillet C, Fournier I, Berteloot L, Carcelain G, Godreuil S, Blanche S, Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP.

Pediatrics. 2019 Sep;144(3). pii: e20182065. doi: 10.1542/peds.2018-2065.

PMID:
31455612
2.

[HIV Disclosure to the Child/Adolescent in Central and West Francophone Africa].

Dahourou DL, Masson D, Aka-Dago-Akribi H, Gauthier-Lafaye C, Cacou C, Raynaud JP, Moh C, Bouah B, Sturm G, Oga M, Msellati P, Leroy V; Le Groupe Atelier Annonce Adolescents Afrique.

Bull Soc Pathol Exot. 2019;112(1):14-21. doi: 10.3166/bspe-2019-0063. French.

PMID:
31225728
3.

Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.

Diallo MSK, Rabilloud M, Ayouba A, Touré A, Thaurignac G, Keita AK, Butel C, Kpamou C, Barry TA, Sall MD, Camara I, Leroy S, Msellati P, Ecochard R, Peeters M, Sow MS, Delaporte E, Etard JF; Contactebogui Study Group.

Lancet Infect Dis. 2019 Mar;19(3):308-316. doi: 10.1016/S1473-3099(18)30649-2. Epub 2019 Feb 11.

PMID:
30765243
4.

High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal.

Cissé AM, Laborde-Balen G, Kébé-Fall K, Dramé A, Diop H, Diop K, FatouNiasse-Traoré, Coulibaly M, Have NN, Vidal N, Thiam S, Wade AS, Peeters M, Taverne B, Msellati P, Touré-Kane C.

BMC Pediatr. 2019 Feb 5;19(1):47. doi: 10.1186/s12887-019-1420-z.

5.

Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis.

Borand L, de Lauzanne A, Nguyen NL, Cheng S, Pham TH, Eyangoh S, Ouedraogo AS, Ung V, Msellati P, Tejiokem M, Nacro B, Inghammar M, Dim B, Delacourt C, Godreuil S, Blanche S, Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group.

Clin Infect Dis. 2019 May 2;68(10):1750-1753. doi: 10.1093/cid/ciy897.

6.

Living with HIV at the time of its normalization: a routine experience for women?

Servais S, Desclaux A, Berthé A, Bila B, Msellati P.

Med Sante Trop. 2018 Aug 1;28(3):307-311. doi: 10.1684/mst.2018.0815.

7.

Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.

Cames C, Pascal L, Ba A, Mbodj H, Ouattara B, Diallo NF, Msellati P, Mbaye N, Sy Signate H, Blanche S, Diack A; MAGGSEN Cohort Study Group.

BMC Infect Dis. 2018 Aug 6;18(1):374. doi: 10.1186/s12879-018-3282-7.

8.

Value of chest X-ray in TB diagnosis in HIV-infected children living in resource-limited countries: the ANRS 12229-PAANTHER 01 study.

Berteloot L, Marcy O, Nguyen B, Ung V, Tejiokem M, Nacro B, Goyet S, Dim B, Blanche S, Borand L, Msellati P, Delacourt C.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):844-850. doi: 10.5588/ijtld.18.0122.

PMID:
29991391
9.

Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study.

Marcy O, Tejiokem M, Msellati P, Truong Huu K, Do Chau V, Tran Ngoc D, Nacro B, Ateba-Ndongo F, Tetang-Ndiang S, Ung V, Dim B, Neou L, Berteloot L, Borand L, Delacourt C, Blanche S; ANRS 12229 PAANTHER 01 Study Group.

Lancet HIV. 2018 Feb;5(2):e87-e95. doi: 10.1016/S2352-3018(17)30206-0. Epub 2017 Nov 23.

PMID:
29174612
10.

Prevention of Mother-to-Child Transmission of HIV in Yaounde: Barrier to Care.

Landefeld CC, Fomenou LA, Ateba F, Msellati P.

AIDS Care. 2018 Jan;30(1):116-120. doi: 10.1080/09540121.2017.1390540. Epub 2017 Oct 16.

PMID:
29034724
11.

Virologic Response to Early Antiretroviral Therapy in HIV-infected Infants: Evaluation After 2 Years of Treatment in the Pediacam Study, Cameroon.

Ateba Ndongo F, Texier G, Ida Penda C, Tejiokem MC, Tetang Ndiang S, Ndongo JA, Guemkam G, Sofeu CL, Kfutwah A, Faye A, Msellati P, Warszawski J; ANRS-Pediacam Study Group.

Pediatr Infect Dis J. 2018 Jan;37(1):78-84. doi: 10.1097/INF.0000000000001745.

PMID:
28841582
12.

Stunting among children under 3 years of age in Côte d'Ivoire: spatial and temporal variations between 1994 and 2011.

Barankanira E, Molinari N, Msellati P, Laurent C, Bork KA.

Public Health Nutr. 2017 Jun;20(9):1627-1639. doi: 10.1017/S1368980017000544. Epub 2017 Apr 3.

PMID:
28367794
13.

Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea.

Subtil F, Delaunay C, Keita AK, Sow MS, Touré A, Leroy S, Msellati P, Magassouba N, Baize S, Raoul H, Ecochard R, Barry M, Delaporte E, Etard JF; Postebogui Study Group.

Clin Infect Dis. 2017 Jun 15;64(12):1788-1790. doi: 10.1093/cid/cix210.

PMID:
28329169
14.

Risk Factors for Growth Retardation in HIV-infected Senegalese Children on Antiretroviral Treatment: The ANRS 12279 MAGGSEN Pediatric Cohort Study.

Cames C, Pascal L, Diack A, Mbodj H, Ouattara B, Diagne NR, Diallo NF, Msellati P, Mbaye N, Sy Signate H; MAGGSEN Cohort Study Group.

Pediatr Infect Dis J. 2017 Apr;36(4):e87-e92. doi: 10.1097/INF.0000000000001454.

PMID:
28187062
15.

Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study.

Etard JF, Sow MS, Leroy S, Touré A, Taverne B, Keita AK, Msellati P, Magassouba N, Baize S, Raoul H, Izard S, Kpamou C, March L, Savane I, Barry M, Delaporte E; Postebogui Study Group.

Lancet Infect Dis. 2017 May;17(5):545-552. doi: 10.1016/S1473-3099(16)30516-3. Epub 2017 Jan 14.

PMID:
28094208
16.

Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets.

Boullé C, Guichet E, Kouanfack C, Aghokeng A, Onambany B, Ikaka CM, Ngock E, Tsoumsta L, Msellati P, Mpoudi-Ngolé E, Peeters M, Delaporte E, Laurent C.

Open Forum Infect Dis. 2016 Dec 20;3(4):ofw233. doi: 10.1093/ofid/ofw233. eCollection 2016 Oct.

17.

Acceptability of Outpatient Ready-To-Use Food-Based Protocols in HIV-Infected Senegalese Children and Adolescents Within the MAGGSEN Cohort Study.

Cames C, Varloteaux M, Have NN, Diom AB, Msellati P, Mbaye N, Mbodj H, Sy Signate H, Diack A; ANRS 12279 MAGGSEN Cohort Study Group.

Food Nutr Bull. 2017 Mar;38(1):27-36. doi: 10.1177/0379572116679053. Epub 2016 Nov 23.

PMID:
27881690
18.

New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors.

Sow MS, Etard JF, Baize S, Magassouba N, Faye O, Msellati P, Touré A 2nd, Savane I, Barry M, Delaporte E; Postebogui Study Group.

J Infect Dis. 2016 Nov 15;214(10):1475-1476. Epub 2016 May 3.

PMID:
27142204
19.

[Revival after Ebola: multidisciplinary assessment at 1 year, prospect and follow-up study of surviving patients from Ebola in Guinea (PostEboGui cohort)].

Msellati P, Touré A, Sow MS, Cécé K, Taverne B, Desclaux A, Barry M, Etard JF, Delaporte E; Groupe d’études PostEboGui.

Bull Soc Pathol Exot. 2016 Oct;109(4):236-243. Epub 2016 Oct 3. French.

PMID:
27704472
20.

[Impediments to HIV testing in HIV-infected children and teenagers in Africa: look for them where they are!].

Msellati P, Ateba Ndongo F, Hejoaka F, Nacro B.

Med Sante Trop. 2016 Jan-Mar;26(1):10-4. doi: 10.1684/mst.2015.0519. French.

21.

Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.

Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, Nguyen Thi NL, Nacro B, Cheng S, Eyangoh S, Pham TH, Ouedraogo AS, Tarantola A, Godreuil S, Blanche S, Delacourt C.

Clin Infect Dis. 2016 May 1;62(9):1161-1168. doi: 10.1093/cid/ciw036. Epub 2016 Feb 7.

PMID:
26908804
22.

Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?

Ateba Ndongo F, Warszawski J, Texier G, Penda I, Tetang Ndiang S, Ndongo JA, Guemkam G, Sofeu CL, Kfutwah A, Faye A, Msellati P, Tejiokem MC; ANRS-PEDIACAM study group.

BMC Pediatr. 2015 Sep 21;15:132. doi: 10.1186/s12887-015-0451-3.

23.

Predictors of depression among patients on art in a rural health district in North West Cameroon.

Asangbeh SL, Sobngwi JL, Ekali GL, Eyoum C, Msellati P.

AIDS Care. 2016;28(2):205-8. doi: 10.1080/09540121.2015.1074654. Epub 2015 Aug 19.

PMID:
26288104
24.

[HIV/AIDS stigma in Africa: analysis of its forms and manifestations in Burkina Faso].

Ky-Zerbo O, Desclaux A, Somé JF, El Asmar K, Msellati P, Obermeyer CM.

Sante Publique. 2014 May-Jun;26(3):375-84. French.

25.

HIV-1 DNA concentrations and evolution among African HIV-1-infected children under antiretroviral treatment (ANRS 1244/1278).

Boullé C, Rouet F, Fassinou P, Msellati P, Debeaudrap P, Chaix ML, Rouzioux C, Avettand-Fenoel V.

J Antimicrob Chemother. 2014 Nov;69(11):3047-50. doi: 10.1093/jac/dku274. Epub 2014 Jul 17.

PMID:
25038068
26.

[Sexual behavior and condom use by people living with HIV/AIDS in Gabon].

Yaba W, Msellati P, Chippaux JP.

Sante Publique. 2013 Nov-Dec;25(6):839-47. French.

PMID:
24451430
27.

24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.

Hien H, Meda N, Diagbouga S, Zoure E, Yaméogo S, Tamboura H, Somé J, Ouiminga A, Rouet F, Drabo A, Hien A, Nicolas J, Chappuy H, Van de Perre P, Msellati P, Nacro B.

Afr Health Sci. 2013 Jun;13(2):287-94. doi: 10.4314/ahs.v13i2.13.

28.

[Alternative medicine, beliefs, and management of people with HIV in Gabon].

Yaba W, Chippaux JP, Obiang-Ndong GP, Msellati P.

Med Sante Trop. 2013 Oct-Dec;23(4):403-11. doi: 10.1684/mst.2013.0247. French.

29.

A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.

Bouazza N, Tréluyer JM, Msellati P, Van de Perre P, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Hirt D, Urien S.

AIDS. 2013 Mar 13;27(5):761-8. doi: 10.1097/QAD.0b013e32835caad1.

PMID:
23719348
30.

Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.

De Beaudrap P, Boullé C, Lewden C, Gabillard D, Nacro B, Diagbouga S, Fassinou P, Hien H, Laurent C, Msellati P; ANRS 12222 Morbidity/Mortality Study Group.

Pediatr Infect Dis J. 2013 Apr;32(4):354-60. doi: 10.1097/INF.0b013e318278b222.

PMID:
23099424
31.

[Self-disclosure of a HIV-positive serostatus: factors favoring disclosure and consequences for persons living with HIV/AIDS in Burkina Faso].

Kouanda S, Yaméogo WM, Berthé A, Bila B, Bocoum Yaya FK, Somda A, Doulougou B, Sanou MJ, Sondo B, Msellati P.

Rev Epidemiol Sante Publique. 2012 Jun;60(3):221-8. doi: 10.1016/j.respe.2011.12.135. Epub 2012 May 15. French.

PMID:
22595419
32.

Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis.

Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, Essex M, Ekouevi DK, Jackson D, Coutsoudis A, Kilewo C, Leroy V, Wiktor SZ, Nduati R, Msellati P, Zaba B, Ghys PD, Newell ML; UNAIDS Child Survival Group.

PLoS One. 2012;7(2):e28510. doi: 10.1371/journal.pone.0028510. Epub 2012 Feb 23.

33.

[Family environment and dental health disparities among urban children in Burkina Faso].

Varenne B, Fournet F, Cadot E, Msellati P, Ouedraogo HZ, Meyer PE, Cornu JF, Salem G, Petersen PE.

Rev Epidemiol Sante Publique. 2011 Dec;59(6):385-92. doi: 10.1016/j.respe.2011.07.002. Epub 2011 Oct 14. French.

PMID:
22000043
34.

Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.

Barro M, Some J, Foulongne V, Diasso Y, Zouré E, Hien H, François R, Michel S, Drabo A, Tamboura H, Ouiminga A, Diagbouga S, Hien A, Yaméogo S, Van De Perre P, Nacro B, Msellati P.

J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S44-9. doi: 10.1097/QAI.0b013e31821fd64f.

PMID:
21857286
35.

Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.

Nacro B, Zoure E, Hien H, Tamboura H, Rouet F, Ouiminga A, Drabo A, Yameogo S, Hien A, Peyriere H, Mathieu O, Hirt D, Treluyer JM, Nicolas J, Foulongne V, Segondy M, van de Perre P, Diagbouga S, Msellati P.

Bull World Health Organ. 2011 Jun 1;89(6):451-8. doi: 10.2471/BLT.10.081646. Epub 2011 Apr 6.

36.

Evolution of lipid levels in HIV-infected children treated or not with HAART in Abidjan, Cote d'Ivoire.

Cournil A, Mercier-Deheuvels S, Dupuy AM, Cristol JP, Anaky MF, Rouet F, Fassinou P, Msellati P.

J Trop Pediatr. 2012 Feb;58(1):43-9. doi: 10.1093/tropej/fmr038. Epub 2011 May 10.

PMID:
21558308
37.

Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa.

Marston M, Becquet R, Zaba B, Moulton LH, Gray G, Coovadia H, Essex M, Ekouevi DK, Jackson D, Coutsoudis A, Kilewo C, Leroy V, Wiktor S, Nduati R, Msellati P, Dabis F, Newell ML, Ghys PD.

Int J Epidemiol. 2011 Apr;40(2):385-96. doi: 10.1093/ije/dyq255. Epub 2011 Jan 18.

38.

User fees and access to ARV treatment for persons living with HIV/AIDS: implementation and challenges in Burkina Faso, a limited-resource country.

Kouanda S, Bocoum FY, Doulougou B, Bila B, Yameogo M, Sanou MJ, Sawadogo M, Sondo B, Msellati P, Desclaux A.

AIDS Care. 2010 Sep;22(9):1146-52. doi: 10.1080/09540121003605047.

PMID:
20824567
39.

Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?

Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Tréluyer JM, Msellati P, Urien S.

Antimicrob Agents Chemother. 2010 Aug;54(8):3280-6. doi: 10.1128/AAC.00306-10. Epub 2010 Jun 1.

40.

[Do commercial sex workers who discuss treatment with family and friends adhere to it better?].

Sanon A, Traoré I, Diallo R, Ouédraogo A, Andonaba J, Konate I, Berthe A, Huet C, Msellati P, Visier L, Mayaud P, Nagot N; Groupe d'etude Yerelon.

Sante. 2009 Apr-Jun;19(2):95-9. doi: 10.1684/san.2009.0153. French.

41.

Contextual or universal ethics: a non-issue? Viewpoint.

Anglaret X, Msellati P.

J Int Bioethique. 2009 Mar-Jun;20(1-2):65-74, 164-5.

PMID:
19803066
42.

Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?

Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, Zoure E, Rouet F, Hien H, Msellati P, Van De Perre P, Tréluyer JM.

Antimicrob Agents Chemother. 2009 Oct;53(10):4407-13. doi: 10.1128/AAC.01594-08. Epub 2009 Jul 27.

43.

Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.

Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Urien S, Foulongne V, Van De Perre P, Tréluyer JM, Msellati P.

Antimicrob Agents Chemother. 2009 Oct;53(10):4399-406. doi: 10.1128/AAC.01187-08. Epub 2009 Jul 6.

44.

Women, mothers and HIV care in resource-poor settings.

Desclaux A, Msellati P, Walentowitz S.

Soc Sci Med. 2009 Sep;69(6):803-6. doi: 10.1016/j.socscimed.2009.05.036. Epub 2009 Jul 3. No abstract available.

PMID:
19577832
45.

Improving mothers' access to PMTCT programs in West Africa: a public health perspective.

Msellati P.

Soc Sci Med. 2009 Sep;69(6):807-12. doi: 10.1016/j.socscimed.2009.05.034. Epub 2009 Jun 17.

PMID:
19539413
46.

Relationship of CD4+ T-cell counts and plasma HIV-1 RNA levels with serological HBeAg/anti-HBe patterns obtained in West-African HBV-HIV-1-co-infected children.

Rouet F, Chaix ML, Kpozehouen A, Inwoley A, Anaky MF, Fassinou P, Rouzioux C, Blanche S, Msellati P.

J Trop Pediatr. 2009 Dec;55(6):409-12. doi: 10.1093/tropej/fmp034. Epub 2009 May 15.

PMID:
19447821
47.

Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.

Walenda C, Kouakoussui A, Rouet F, Wemin L, Anaky MF, Msellati P.

J Trop Pediatr. 2009 Jun;55(3):170-6. doi: 10.1093/tropej/fmn106. Epub 2008 Dec 9.

PMID:
19066169
48.

Maternal HIV infection and infant feeding: support is the key.

Msellati P, Van de Perre P.

AIDS. 2008 Nov 12;22(17):2391-2. doi: 10.1097/QAD.0b013e328312c77e. No abstract available.

PMID:
18981779
49.

The unique features of pediatric HIV-1 in sub-Saharan Africa.

De Baets AJ, Ramet J, Msellati P, Lepage P.

Curr HIV Res. 2008 Jun;6(4):351-62.

PMID:
18691033
50.

CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Côte d'Ivoire.

De Beaudrap P, Rouet F, Fassinou P, Kouakoussui A, Mercier S, Ecochard R, Msellati P.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):70-6. doi: 10.1097/QAI.0b013e3181831847.

PMID:
18667922

Supplemental Content

Loading ...
Support Center